oncolyt
viru
immunotherapi
therapeut
approach
cancer
treatment
util
nativ
genet
modifi
virus
select
replic
within
tumour
cell
abil
virus
kill
cancer
cell
recogn
nearli
centuri
past
decad
clinic
trial
document
therapeut
benefit
patient
cancer
interest
oncolyt
virus
increas
base
better
understand
viral
biolog
tumour
immunolog
molecular
genet
furthermor
recent
random
phase
iii
clinic
trial
demonstr
improv
durabl
respons
rate
patient
advanc
melanoma
treat
modifi
herp
simplex
viru
type
encod
granulocytemacrophag
colonystimul
factor
gmcsf
viru
term
talimogen
laherparepvec
tvec
amgen
wide
anticip
first
oncolyt
viru
immuno
therapi
approv
us
food
drug
administr
fda
treatment
cancer
success
tvec
like
promot
drug
develop
within
new
class
cancer
therapeut
nearli
million
vertebr
virus
approxim
thought
infect
mammalian
cell
virus
sever
share
properti
includ
genet
element
compos
singleor
doublestrand
dna
rna
abil
infect
host
cell
replic
permiss
condit
tabl
outcom
viral
infect
highli
variabl
depend
pathogen
natur
viral
encod
gene
interact
viru
host
immun
system
abil
viru
replic
andor
induc
latenc
follow
infect
insight
mechan
viral
entri
replic
induct
andor
suppress
immun
respons
lytic
versu
latent
infect
led
intens
interest
util
virus
treatment
human
diseas
use
select
oncolyt
vector
treatment
specif
type
cancer
contrast
standard
viralbas
vaccin
oncolyt
virus
directli
infect
lyse
tumour
cell
situ
necessarili
requir
defin
antigen
includ
vector
tumourassoci
antigen
may
releas
die
tumour
cell
oncolyt
virus
also
provid
addit
danger
signal
promot
effici
antitumour
immun
respons
although
incomplet
understood
oncolyt
virus
thought
mediat
antitumour
activ
two
distinct
mechan
action
select
replic
within
neoplast
cell
result
direct
lytic
effect
tumour
cell
induct
system
antitumour
immun
rel
contribut
mechan
may
differ
depend
natur
type
cancer
cell
characterist
viral
vector
interact
viru
tumour
microenviron
host
immun
system
certain
virus
abil
enter
cancer
cell
select
replic
within
cell
although
oncolyt
virus
enter
normal
cancer
cell
inher
abnorm
cancer
cell
respons
stress
cell
signal
homeostasi
provid
select
advantag
viral
replic
normal
host
cell
antivir
machineri
respons
detect
clearanc
virus
may
also
abnorm
cancer
cell
exampl
protein
kinas
r
pkr
critic
factor
help
clear
intracellular
viral
infect
pkr
may
absent
cancer
cell
allow
increas
viral
replic
wherea
may
activ
cancer
cell
lowgrad
tumour
differ
influenc
therapeut
activ
oncolyt
viru
immun
respons
oncolyt
virus
appear
import
compon
antitumour
effect
doubleedg
sword
one
hand
virus
help
promot
immun
respons
tumour
cell
allow
tumour
antigen
present
context
activ
viral
infect
hand
neutral
antivir
respons
may
block
viru
replic
ongo
infect
tumour
cell
therapeut
outcom
depend
complex
interplay
oppos
forc
system
immun
fulli
engag
howev
therapeut
respons
may
seen
local
inject
tumour
distant
site
uninfect
tumour
growth
mani
virus
propos
vector
oncolyt
viru
immunotherapi
consider
work
done
optim
viral
vector
attenu
pathogen
enhanc
immunogen
date
adenovirus
poxvirus
coxsackievirus
polioviru
measl
viru
newcastl
diseas
viru
ndv
reoviru
other
enter
earlyphas
clinic
trial
two
virus
tvec
shanghai
sunway
biotech
achiev
regulatori
review
genet
modifi
oncolyt
adenoviru
combin
chemotherapi
approv
treatment
nasopharyng
carcinoma
china
novemb
ref
review
provid
comprehens
overview
critic
issu
develop
oncolyt
viru
immunotherapi
discuss
preclin
clinic
data
support
role
oncolyt
virus
cancer
therapi
detail
uniqu
challeng
oncolyt
virus
drug
develop
intracellular
extracellular
compon
inher
cellular
respons
viral
infect
includ
detect
via
protein
kinas
r
pkr
tolllik
receptor
tlr
retino
acidinduc
gene
other
initi
immun
respons
releas
cytokin
type
interferon
dangerassoci
molecular
pattern
signal
damp
high
mobil
group
box
heat
shock
protein
hsp
other
pathogenassoci
molecular
pattern
pamp
viral
product
recogn
tlr
mechan
oncolyt
virus
mediat
tumour
reject
incomplet
understood
oncolyt
virus
directli
kill
host
tumour
cell
activ
influenc
effici
cell
receptor
target
viral
replic
host
cell
antivir
respons
element
lytic
potenti
oncolyt
virus
also
depend
type
viru
dose
natur
induc
viral
tropism
suscept
cancer
cell
differ
form
cell
death
apoptosi
necrosi
pyroptosi
autophagi
normal
cell
varieti
signal
pathway
oper
detect
clear
pathogen
viral
particl
fig
pathway
stimul
local
interferon
ifn
releas
intracellular
tolllik
receptor
tlr
activ
viral
element
tlr
cell
surfac
intracellular
pattern
recognit
receptor
activ
respons
repeat
sequenc
socal
pathogenassoci
molecular
pattern
pamp
common
pathogen
bacteria
virus
pamp
may
includ
element
viral
capsid
dna
rna
viral
protein
product
tlr
signal
activ
host
cell
antivir
respons
system
innat
immun
sever
downstream
host
cell
factor
involv
oncolyt
viru
clearanc
identifi
includ
tnfassoci
factor
ifnrel
factor
retino
acidinduc
gene
factor
activ
jakstat
janu
kinasesign
transduc
activ
transcript
pathway
coordin
antivir
machineri
infect
cell
antivir
machineri
reinforc
local
ifn
releas
activ
pkr
activ
pkr
intracellular
protein
kinas
recogn
doublestrand
rna
viral
element
activ
viral
element
pkr
termin
cell
protein
synthesi
promot
rapid
cell
death
viral
clearanc
cancer
cell
ifn
pathway
signal
pkr
activ
may
abnorm
viral
clearanc
thwart
induct
system
antitumour
immun
induct
system
innat
tumourspecif
adapt
immun
respons
appear
critic
element
tumour
erad
oncolyt
virus
follow
oncolyt
figur
oncolyt
virus
exploit
cancer
immun
evas
pathway
follow
viral
infect
normal
cell
activ
antivir
pathway
allow
contain
viral
infect
antivir
machineri
trigger
viral
pathogenassoci
molecular
pattern
pamp
activ
tolllik
receptor
tlr
detect
viral
nucleic
acid
retino
acidinduc
gene
viru
detect
signal
cascad
sever
type
interferon
ifn
element
janu
kinas
jak
signal
transduc
activ
transcript
stat
interferon
regulatori
factor
result
program
transcript
pathway
limit
viral
spread
target
infect
cell
apoptosi
necrosi
local
ifn
product
induc
innat
immun
respons
viral
infect
may
also
promot
antivir
activ
ifn
receptor
ifnr
tlr
signal
via
myeloid
differenti
primari
respons
protein
tirdomaincontain
adapterinduc
trif
nuclear
induc
product
proinflammatori
cytokin
type
ifn
type
ifn
signal
jakstat
signal
pathway
result
upregul
cell
cycl
regul
protein
kinas
r
pkr
limit
viral
spread
bind
viral
particl
trigger
type
ifn
transcript
pathway
promot
abort
apoptosi
infect
cell
product
cytokin
alert
immun
system
presenc
viral
infect
b
cancer
cell
howev
process
disrupt
cancer
cell
may
downregul
key
signal
compon
within
innat
signal
pathway
includ
ref
limit
detect
viral
particl
tlr
make
cancer
cell
suscept
viral
replic
furthermor
cancer
cell
may
downregul
key
compon
type
ifn
signal
pathway
therebi
limit
proapoptot
cell
cycl
regulatori
effect
type
ifn
although
data
limit
figur
depict
individu
virus
near
factor
andor
pathway
known
promot
viral
elimin
normal
cell
part
support
viral
replic
owe
factor
defici
cancer
cell
part
b
dsrna
doublestrand
rna
ndv
newcastl
diseas
viru
traf
tnfassoci
factor
vsv
vesicular
stomat
viru
process
wherebi
tissu
damag
initi
immun
respons
one
antigen
may
lead
prime
selfreact
andor
b
cell
target
area
epitop
within
initi
antigen
antigen
new
antigen
often
deriv
cell
metabol
pathway
protein
commonli
express
tumour
cell
neoantigen
may
appear
consequ
epitop
spread
follow
initi
immun
attack
tumour
cell
trigger
unrel
antigen
monoclon
antibodi
inhibit
neg
immun
checkpoint
immun
checkpoint
control
import
intracellular
signal
pathway
immun
system
either
activ
inhibit
immun
respons
checkpoint
inhibitor
shown
signific
promis
treatment
cancer
notabl
blockad
cytotox
lymphocyt
antigen
interact
program
cell
death
program
cell
death
ligand
signific
impact
treatment
melanoma
lung
cancer
possibl
mani
cancer
cell
death
tumour
cell
releas
tumourassoci
antigen
serv
promot
adapt
immun
respons
mediat
tumour
regress
distant
tumour
site
expos
viru
also
releas
viral
pamp
addit
cellular
dangerassoci
molecular
pattern
signal
damp
exampl
heat
shock
protein
high
mobil
group
box
protein
calreticulin
atp
uric
acid
cytokin
exampl
type
ifn
tumour
necrosi
promot
matur
antigenpres
cell
apc
dendrit
cell
activ
antigenspecif
cell
respons
activ
cell
expand
cytotox
effector
cell
abil
traffic
site
establish
tumour
growth
mediat
antitumour
immun
upon
antigen
recognit
fig
howev
natur
abil
virus
induc
host
antivir
immun
respons
may
result
clearanc
viru
neutral
antivir
antibodi
andor
cytotox
tcellmedi
immun
respons
extent
viral
neutral
influenc
induct
tumour
immun
complex
influenc
mani
variabl
notabl
characterist
viru
tumour
microenviron
releas
tumourassoci
antigen
especi
combin
local
cytokin
damp
releas
benefici
induc
innat
adapt
immun
respons
cancer
cell
fig
effect
may
especi
import
mediat
tumour
regress
distant
tumour
site
inject
expos
viru
preclin
studi
demonstr
import
tumourspecif
cell
mediat
tumour
reject
oncolyt
virus
type
ifn
damp
also
directli
activ
natur
killer
nk
cell
part
innat
immun
respons
nk
cell
kill
target
cell
downregul
major
histocompat
complex
mhc
class
express
common
occurr
cancer
cell
influenc
nk
cell
may
depend
host
speci
characterist
viru
furthermor
nk
cell
may
detriment
effect
oncolyt
virus
elimin
viral
infect
cell
factor
influenc
balanc
immunemedi
viral
clearanc
induct
antitumour
immun
incomplet
understood
counteract
cancermedi
immun
evas
cancer
cell
evolv
sophist
strategi
avoid
immunemedi
destruct
exampl
tumour
cell
microenviron
express
immuneinhibitori
surfac
receptor
inactiv
effector
immun
cell
secret
factor
transform
growth
ido
facilit
recruit
immunesuppress
cell
tumourassoci
macrophag
myeloidderiv
suppressor
cell
site
tumour
growth
oncolyt
virus
modifi
suppress
microenviron
varieti
mechan
alter
cytokin
milieu
type
immun
cell
within
tumour
microenviron
chang
promot
immunemedi
tumour
cell
recognit
erad
trigger
tumourassoci
antigen
epitop
spread
presenc
danger
signal
tlr
engag
level
type
ifn
inflammatori
mediat
increas
potenti
system
immun
cancer
kill
cancer
cell
result
releas
novel
cancer
antigen
neoantigen
may
previous
hidden
immun
system
restrict
present
fig
effect
recent
report
follow
treatment
cancer
patient
immunotherapeut
cell
checkpoint
inhibitor
neoantigen
may
taken
local
apc
context
proinflammatori
environ
trigger
immun
respons
neoantigen
new
cell
clone
gener
may
abl
circul
kill
antigenexpress
cancer
cell
includ
cancer
cell
infect
viru
immun
respons
also
associ
immuneassoci
bystand
effect
local
releas
cytotox
perforin
granzym
may
result
kill
nearbi
tumour
cell
even
absenc
direct
antigen
express
distinct
viru
bystand
effect
relat
replic
viru
insid
cancer
cell
spread
previous
uninfect
cancer
cell
physic
barrier
reduc
spread
oncolyt
virus
includ
necrosi
calcif
hypoxia
acidosi
increas
proteolyt
activ
high
interstiti
pressur
furthermor
tumour
dens
extracellular
matrix
poorli
vascular
major
clinic
studi
oncolyt
virus
adenoviru
poxviru
measl
reoviru
use
intratumour
inject
bypass
tumour
architectur
barrier
howev
intratumour
inject
limit
tumour
physic
access
clinic
palpat
direct
imag
discuss
inject
oncolyt
viru
one
tumour
lesion
induc
system
antitumour
respons
overcom
physic
limit
evidenc
tvec
optim
phase
iii
clinic
trial
virus
seneca
valley
viru
deliv
intraven
natur
resist
haemagglutin
process
result
prematur
viral
clearanc
reduc
deliveri
tumour
site
follow
intraven
deliveri
bloodbrain
barrier
may
limit
abil
virus
mani
drug
reach
primari
brain
tumour
brain
metastas
may
overcom
direct
inject
central
nervou
system
cn
tumour
use
extern
reservoir
commun
site
brain
tumour
parvoviru
natur
cross
bloodbrain
barrier
allow
deliveri
oncolyt
viru
via
intravascular
rout
parvoviru
use
clinic
trial
glioblastoma
multiform
gbm
like
permiss
infect
stromal
cell
cancerassoci
fibroblast
may
infect
oncolyt
virus
nonpermiss
viral
replic
thu
fibroblast
may
act
decoy
reservoir
oncolyt
virus
reduc
deliveri
infecti
virion
cancer
cell
anoth
mechan
may
limit
overal
effect
oncolyt
virus
suscept
cancer
cell
apoptosi
may
induc
viral
infect
factor
cell
undergo
apoptosi
rapidli
reduc
time
viral
replic
propag
decreas
amount
activ
viru
tumour
ultim
limit
activ
intratumour
dose
oncolyt
virus
live
viral
particl
overal
design
oncolyt
viru
strategi
must
consid
approach
tumour
cell
target
attenu
viral
pathogenesi
well
approach
limit
viral
immunogen
promot
tumour
cell
kill
immunogen
flexibl
recombin
engin
allow
explor
number
strategi
enhanc
effect
oncolyt
virus
mani
oncolyt
virus
current
clinic
natur
tropism
cell
surfac
protein
aberrantli
express
cancer
cell
fig
exampl
use
herpesviru
entri
mediat
hvem
select
nectin
cell
entri
surfac
receptor
overexpress
cancer
cell
includ
melanoma
variou
carcinoma
measl
viru
specif
edmonston
strain
util
surfac
receptor
cell
entri
normal
function
prevent
cell
elimin
inactiv
complement
pathway
immun
system
often
overexpress
cancer
cell
coxsackieviru
enter
cell
via
intercellular
adhes
molecul
also
known
decay
acceler
factor
daf
also
known
overexpress
cancer
multipl
myeloma
melanoma
breast
cancer
although
coxsackievirus
may
also
use
nectin
cell
entri
echoviru
member
enteroviru
famili
increas
specif
ovarian
cancer
cell
use
domain
integrin
cell
entri
overexpress
cell
anoth
member
enteroviru
famili
polioviru
enhanc
specif
variou
cancer
target
receptor
potenti
impair
antitumour
nk
cell
respons
overexpress
cancer
cell
sindbi
viru
member
togavirida
famili
target
cancer
cell
overexpress
kda
laminin
receptor
promot
cancer
cell
invas
motil
oncolyt
virus
also
engin
directli
target
uniqu
cell
surfac
receptor
express
cancer
cell
exampl
includ
adenoviru
modifi
bind
integrin
highli
express
ovarian
cancer
cell
current
investig
clinic
trial
exampl
engin
specif
includ
lentivirus
pseudotyp
modifi
glycoprotein
sindbi
viru
shown
increas
specif
human
melanoma
mous
xenograft
model
furthermor
measl
viru
engin
express
singlechain
antibodi
recogn
carcinoembryon
antigen
cea
tumour
antigen
select
express
certain
adenocarcinoma
number
molecular
target
promot
viru
accumul
replic
within
tumour
cell
exampl
tumour
cell
frequent
overexpress
b
cell
lymphoma
bcl
famili
cell
surviv
protein
hallmark
neoplast
transform
ndv
target
cancer
cell
overexpress
bclx
l
overexpress
protein
prevent
apoptosi
thu
permit
incub
time
need
viru
multipli
form
syncytia
requir
viral
spread
addit
bcl
famili
ra
signal
pathway
regul
mani
aspect
carcinogenesi
includ
resist
cell
death
prolifer
fig
reoviru
vaccinia
viru
show
natur
select
cancer
cell
overact
ra
signal
pathway
normal
healthi
cell
reoviru
abl
enter
cell
begin
produc
viral
rna
activ
pkr
pathway
activ
pkr
turn
inhibit
protein
translat
prevent
product
viral
particl
stop
spread
viru
howev
rastransform
cancer
cell
initi
pkr
pathway
render
cancer
cell
permiss
viral
infect
ultim
cell
lysi
attenu
oncolyt
viru
viral
gene
encod
uniqu
short
glycoprotein
delet
result
preferenti
lysi
tumour
cell
compar
normal
cell
occur
part
delet
render
unabl
block
pkr
phosphoryl
replic
cell
defect
pkr
signal
vaccinia
viru
member
poxviru
famili
depend
epiderm
growth
factor
receptor
egfr
induc
ra
signal
viral
replic
poxvirus
encod
ligand
trigger
egfr
signal
cancer
cell
overexpress
egfr
therefor
augment
ra
signal
permiss
vaccinia
viru
infect
cancer
cell
often
defect
antivir
mechan
base
type
ifn
signal
provid
virus
replic
advantag
cancer
cell
includ
vaccinia
viru
ndv
rabbit
myxoma
viru
mump
alphavirus
vesicular
stomat
viru
vsv
variant
type
ifn
critic
antivir
antitumour
respons
healthi
cell
promot
immun
respons
clear
viru
also
reduc
cellular
prolifer
activ
proapoptot
protein
ref
multipl
type
cancer
inactiv
pathway
either
reduc
express
type
ifn
limit
type
ifn
signal
via
reduc
receptor
express
alter
downstream
signal
fig
thu
oncolyt
virus
increas
specif
cancer
cell
environ
type
ifn
respons
limit
healthi
cell
virus
clear
ifnmedi
respons
oncolyt
virus
also
engin
take
advantag
abnorm
signal
pathway
cancer
cell
insert
promot
activ
cancer
cell
tissuerestrict
exampl
adenoviru
adenovir
protein
inhibit
cell
cycl
place
control
promot
prostatespecif
antigen
psa
current
evalu
patient
optim
method
administr
oncolyt
virus
establish
clinic
trial
util
direct
inject
establish
tumour
evalu
intraven
deliveri
oncolyt
virus
capabl
replic
limit
number
tumour
cell
need
infect
signific
bystand
effect
anticip
local
replic
viru
releas
surround
tumour
viral
particl
infect
new
tumour
cell
host
antivir
immun
respons
neutral
viru
infect
may
continu
propag
inclus
suicid
gene
within
oncolyt
viru
enhanc
bystand
effect
achiev
much
greater
cell
kill
howev
contribut
bystand
effect
overal
therapeut
effect
oncolyt
viru
need
demonstr
random
clinic
trial
fulli
evalu
prostat
cancer
viru
produc
healthi
cell
cell
undergo
apoptosi
therebi
restrict
viral
prolifer
healthi
tissu
howev
prostat
cancer
cell
psa
promot
highli
activ
select
express
result
prolifer
adenoviru
virusmedi
cell
lysi
similar
manner
oncolyt
adenoviru
engin
express
control
human
telomeras
revers
transcriptas
tert
promot
activ
larg
number
cancer
furthermor
two
bind
site
transcript
factor
regul
cell
cycl
includ
tert
promot
restrict
prolifer
activ
divid
cell
anoth
exampl
oncolyt
adenoviru
replic
restrict
retinoblastoma
rb
defect
cell
common
mutat
cancer
express
place
regul
promot
healthi
cell
rb
inhibit
thu
inhibit
transcript
furthermor
adenovirus
engin
select
replic
hypox
environ
found
insid
tumour
place
gene
transcript
regul
hypoxiainduc
transcript
factor
strategi
shown
effect
murin
xenograft
model
glioma
sever
oncolyt
adenovirus
includ
design
delet
gene
code
protein
bind
inactiv
proapoptot
protein
ref
thu
healthi
cell
infect
virus
undergo
mediat
abort
apoptosi
wherea
cancer
cell
commonli
inactiv
remain
suscept
viral
infect
furthermor
adenovirus
preferenti
prolifer
lyse
cancer
cell
account
nearli
cancer
anoth
approach
improv
postentri
tumour
specif
encod
synthet
mirna
target
sequenc
mirt
untransl
region
utr
fusion
gene
measl
viru
sequenc
bind
cellular
microrna
mi
rna
repress
viral
replic
normal
cancer
cell
exhibit
differenti
express
cognat
mirna
element
engin
oncolyt
viru
mirt
block
replic
normal
cell
specif
mi
rna
express
construct
attenu
viral
pathogenesi
oncolyt
virus
live
virus
potenti
caus
acut
toxic
case
latent
infect
chronic
diseas
although
oncolyt
activ
may
profound
process
confer
select
advantag
oncolyt
virus
ndv
allow
time
viral
replic
cdk
cyclindepend
kinas
egfr
epiderm
growth
factor
receptor
erk
extracellular
signalregul
kinas
mapk
mitogenactiv
protein
kinas
mek
mapkerk
kinas
pdgfr
plateletderiv
growth
factor
receptor
caspaseindepend
form
cell
death
cell
may
undergo
preprogram
seri
intracellular
signal
event
lead
cell
death
well
describ
induct
apoptosi
caspasedepend
signal
cell
howev
may
undergo
caspaseindepend
form
cell
death
cathepsin
induc
death
programm
cell
still
controversi
whether
cathepsinmedi
cell
death
due
apoptosi
form
cell
death
nativ
virus
potenti
viral
pathogenesi
may
also
high
result
limit
benefitrisk
ratio
potenti
pathogen
highli
depend
viru
presenc
natur
engin
attenu
factor
exampl
virul
immuneevas
latencypromot
gene
host
immun
respons
date
seriou
advers
event
report
clinic
trial
followup
patient
often
short
incomplet
clinic
relev
oncolyt
virus
util
attenu
vector
natur
occur
less
virul
variant
particular
virus
prevent
acut
longterm
toxic
exampl
latter
variant
avian
viru
ndv
test
clinic
trial
gbm
see
supplementari
inform
tabl
edmonston
strain
measl
viru
commonli
use
prophylact
measl
vaccin
select
clinic
trial
patient
gbm
tabl
exampl
engin
attenu
oncolyt
viru
tvec
known
caus
neuro
virul
latent
infect
toxic
mediat
viral
gene
product
counteract
type
ifn
respons
antagon
pkr
signal
pathway
within
nondivid
cell
delet
tvec
mean
abl
grow
within
neuron
mediat
latent
infect
date
report
latent
infect
tvec
attenu
vector
vaccinia
viru
also
attenu
limit
lytic
activ
cancer
cell
nonattenu
vaccinia
viru
infect
viral
protein
term
vaccinia
growth
factor
vgf
secret
act
host
egfr
activ
ra
signal
pathway
activ
promot
cellular
prolifer
lead
increas
product
thymidin
kinas
tk
help
promot
viral
replic
howev
attenu
vaccinia
viru
delet
vgf
make
replic
normal
cell
difficult
allow
viral
prolifer
cell
aberr
egfrra
signal
frequent
found
cancer
cell
anoth
compon
necessari
infect
healthi
cell
vaccinia
protein
block
type
ifn
signal
attenu
vaccinia
viru
delet
healthi
cell
becom
suscept
type
ifn
antivir
respons
infect
limit
howev
cancer
cell
commonli
disrupt
type
ifn
pathway
evad
immun
system
thu
suscept
infect
subsequ
lysi
furthermor
delet
may
increas
activ
oncolyt
vaccinia
viru
type
ifn
produc
result
vaccinia
infect
tumour
block
contrast
delet
pathogen
viral
gene
express
virul
gene
also
restrict
tumour
tissu
incorpor
promot
regul
express
virul
gene
describ
adenovirus
engin
express
limit
tumour
cell
transcript
regul
tumourspecif
promot
although
revers
nativ
viru
natur
homolog
recombin
remain
theoret
concern
evid
happen
clinic
augment
antitumour
immun
process
tumour
clearanc
immun
stimul
critic
antitumour
activ
oncolyt
virus
sever
strategi
devis
engin
oncolyt
virus
effect
stimul
antitumour
immun
respons
exampl
antitumour
immun
respons
augment
viral
express
proinflammatori
cytokin
andor
cell
costimulatori
molecul
strategi
well
describ
virus
adenoviru
vaccinia
viru
studi
mice
demonstr
reject
contralater
uninject
flank
tumour
gmcsf
cytokin
promot
dendrit
cell
accumul
matur
engin
viral
genom
gmcsf
thought
improv
tumour
antigen
present
stimul
robust
cell
respons
gmcsf
includ
tvec
adeno
virus
ref
vaccinia
viru
ref
adenoviru
express
heat
shock
protein
cancer
cell
increas
chaperon
protein
proteas
enhanc
protein
degrad
process
use
increas
tumour
antigen
present
approach
may
also
role
epitop
spread
apc
preferenti
take
peptid
bound
oncolyt
virus
tvec
strategi
also
devis
enhanc
immun
respons
delet
protein
block
function
tap
transport
associ
antigen
process
thu
prevent
infect
cell
present
antigen
cell
cancer
glioblastoma
inher
resist
apoptosi
even
infect
virus
owe
dysregul
apoptot
pathway
oncolyt
parvoviru
howev
shown
kill
glioma
cell
activ
immunogen
cathepsinmedi
death
pathway
furthermor
parvoviru
also
induc
immun
respons
gbm
potenti
bystand
effect
involv
increas
inflammatori
cytokin
tumour
antigen
releas
enhanc
lytic
activ
inclus
suicid
gene
gene
render
cell
sensit
apoptosi
therapi
drug
oncolyt
virus
enhanc
abil
directli
kill
cancer
cell
exampl
proapoptot
molecul
tnfrelat
apoptosisinduc
ligand
trail
includ
viral
construct
enhanc
cell
death
trigger
immun
respons
use
tumourenrichedtissuespecif
promot
preferenti
express
suicid
gene
cancer
cell
success
limit
side
effect
improv
therapeut
effect
oncolyt
virus
sever
preclin
model
exampl
adenoviru
adochsvtk
develop
treatment
bone
tumour
encod
gene
tk
driven
osteocalcin
promot
tk
convert
thymidin
analogu
ganciclovir
monophosph
get
incorpor
dna
replic
cell
result
termin
dna
synthesi
ultim
cell
death
system
express
tk
restrict
cell
activ
osteocalcin
promot
increas
suscept
treatment
thymidin
analogu
ganciclovir
howev
ganciclovir
block
viral
replic
approach
may
inhibit
oncolyt
viru
activ
two
suicid
gene
test
bacteri
cytosin
deaminas
cd
adenoviru
death
protein
adp
cd
transform
cytotox
adp
nuclear
membran
glycoprotein
requir
late
stage
adenoviru
infect
effici
cell
lysi
releas
viral
particl
enhanc
lytic
activ
report
oncolyt
adenoviru
adp
gene
insert
adenovir
locu
result
adp
overexpress
although
immun
stimul
critic
antitumour
activ
oncolyt
virus
effect
balanc
potenti
rapid
clearanc
viru
antivir
immun
moreov
human
natur
artifici
vaccin
expos
oncolyt
virus
may
therefor
preexist
neutral
antibodi
cellular
immun
oncolyt
virus
one
strategi
limit
viru
neutral
util
altern
viru
serotyp
multipl
serotyp
exist
adenovirus
vsv
allow
serotyp
switch
inject
prevent
antibodi
neutral
although
measl
viru
natur
switch
serotyp
measl
virus
engin
mimic
serotyp
switch
shown
limit
neutral
antibodi
titr
viru
strategi
overcom
viral
clearanc
includ
pegyl
coval
conjug
polyethylen
glycol
viral
coat
vsv
adenoviru
polym
coat
adenoviru
prevent
antibodi
bind
neutral
polym
coat
adenoviru
reduc
target
cover
viral
protein
requir
cell
entri
simultan
increas
circul
time
investig
also
abl
protect
oncolyt
virus
antibodi
use
cell
carrier
mesenchym
stem
cell
infect
ex
vivo
transfer
back
host
traffick
tumour
site
cell
respons
may
dampen
express
viral
gene
product
block
antigen
present
therebi
limit
detect
cell
prolong
viral
infect
addit
modifi
viru
attempt
made
suppress
host
immun
systemfor
exampl
pretreat
cyclophosphamid
strategi
shown
enhanc
oncolyt
efficaci
hsvin
glioma
model
addit
strategi
avoid
viral
neutral
describ
number
preclin
studi
investig
method
enhanc
oncolyt
viru
bioavail
exampl
treatment
oncolyt
virus
combin
vasoact
vasonorm
treatment
histamin
nitroglycerin
local
hyperthermia
lowdos
paclitaxel
bevacizumab
bradikynin
improv
viral
deliveri
viral
penetr
also
enhanc
pretreat
tumour
microenviron
proteolyt
enzym
hyaluronidas
collagenas
break
sievelik
barrier
pose
extracellular
matrix
ecm
oncolyt
virus
also
engin
express
ecmdegrad
enzym
hyaluronidas
shown
increas
tumour
dissemin
therapeut
activ
melanoma
xenograft
model
furthermor
oncolyt
virus
select
andor
engin
overcom
physic
barrier
interstiti
pressur
acid
hypox
environ
present
tumour
spread
cancer
cell
follow
induct
cell
fusion
process
protect
viru
physic
limit
associ
need
extracellular
propag
limit
infect
intracellular
space
exampl
ndv
coronaviru
orthomyxoviru
paramyxoviru
use
fusogen
membran
glycoprotein
fmg
propag
viral
infect
cell
furthermor
vsv
engin
express
ndv
fusogen
mutant
f
glycoprotein
sindbi
viru
engin
express
hyperfusogen
envelop
glycoprotein
gibbon
ape
leukaemia
viru
convey
fusogenicbas
viral
propag
measl
viru
engin
activ
fusogen
membran
glycoprotein
f
context
high
level
matrix
metalloproteinas
mmp
present
tumour
rather
normal
regul
furin
numer
oncolyt
virus
clinic
develop
see
supplementari
inform
tabl
earlyphas
clinic
trial
restrict
detail
discuss
virus
current
phase
iii
develop
present
adenovirus
herpesvirus
wide
evalu
clinic
member
alphaherpesviru
famili
includ
varicella
speci
doublestrand
dna
viru
larg
genom
kb
kb
encod
gene
essenti
viral
infect
replic
occur
nucleu
howev
caus
insert
mutagenesi
properti
make
attract
candid
oncolyt
viru
develop
howev
major
human
pathogen
caus
skin
lesion
rash
moreov
infect
peripher
nerv
enter
latent
stage
infect
mani
type
cell
includ
epitheli
cell
enter
viral
surfac
glycoprotein
immun
cell
hvem
neuron
surfac
nectin
nectin
nectin
tvec
commerci
advanc
oncolyt
viru
order
reduc
pathogenesi
enhanc
select
tumour
cell
infect
tvec
contain
delet
neurovirul
gene
inhibitor
antigen
present
ref
discuss
critic
block
host
antivir
pkrifn
respons
requir
infect
neuron
tvec
two
gene
delet
improv
cancer
cell
select
prevent
infect
neuron
therebi
significantli
reduc
overal
pathogenesi
delet
result
present
viral
antigen
healthi
cancer
cell
lead
contain
infect
healthi
tissu
immunemedi
destruct
cancer
cell
select
propag
oncolyt
delet
also
induc
earli
activ
promot
block
pkr
phosphoryl
therebi
prevent
cancer
cell
undergo
abort
apoptosi
infect
thu
express
earlier
viral
infect
cycl
increas
oncolyt
therapeut
activ
final
gene
encod
gmcsf
engin
viral
genom
place
gene
improv
induct
antitumour
immun
preclin
studi
tvec
demonstr
potent
lytic
effect
sever
tumour
cell
line
notabl
melanoma
pancreat
cancer
cell
tvec
evalu
advanc
clinic
trial
patient
melanoma
pancreat
cancer
head
neck
tumour
patient
breast
cancer
phase
clinic
trial
multiinstitut
phase
ii
clinic
trial
patient
unresect
stage
iiic
iv
melanoma
treat
initi
dose
pfu
plaqu
form
unit
per
ml
tvec
given
intratumour
inject
allow
seroconvers
follow
week
later
pfu
per
ml
given
everi
week
thereaft
maxim
clinic
respons
unaccept
toxic
diseas
progress
studi
particip
enrol
object
respons
rate
report
gener
lowgrad
constitut
toxic
includ
fever
fatigu
local
inject
site
reaction
tvec
evalu
prospect
random
clinic
phase
iii
trial
patient
unresect
stage
iiib
iiic
iv
melanoma
trial
met
primari
end
point
durabl
respons
rate
defin
object
respons
begin
within
month
treatment
last
least
month
patient
receiv
tvec
compar
patient
given
gmcsf
odd
ratio
p
includ
respons
lesion
inject
noninject
object
respons
rate
report
compar
gmcsftreat
particip
achiev
complet
respons
addit
patient
given
tvec
improv
median
overal
surviv
month
versu
month
gmcsftreat
patient
although
studi
power
surviv
especi
strong
effect
seen
patient
stage
iii
iv
tumour
suggest
tvec
might
particularli
well
suit
treatment
earlystag
patient
less
extens
viscer
diseas
treatment
well
toler
major
advers
event
relat
fever
chill
nausea
fatigu
local
inject
site
reaction
base
result
fda
adviseri
panel
vote
approv
tvec
final
rule
pend
tvec
also
studi
combin
immunotherapeut
ipilimumab
pembrolizumab
patient
melanoma
combin
may
appropri
patient
advanc
heavili
pretreat
diseas
preliminari
data
phase
ib
clinic
trial
tvec
ipilimumab
monoclon
antibodi
block
cytotox
lymphocyt
antigen
cell
checkpoint
inhibitor
report
respons
rate
complet
respons
rate
result
evalu
random
clinic
trial
adenovirus
adenoviru
nake
nonenvelop
doublestrand
dna
viru
linear
genom
kb
encapsul
icosahedr
capsid
virion
diamet
rang
nm
larg
genom
long
dna
sequenc
incorpor
thu
permit
multipl
engin
modif
adenovirus
commonli
infect
human
anim
transmit
aerosol
direct
contact
result
major
popul
seroposit
adenoviru
exposur
although
asymptomat
immunecompet
host
adenovir
infect
caus
diseas
newborn
immunocompromis
patient
adenoviru
enter
cell
use
coxsackieadenoviru
receptor
car
upon
cell
entri
adenoviru
traffic
nucleu
express
adenovir
earli
gene
encod
necessari
viral
propag
specif
target
tumour
suppressor
retinoblastomaassoci
protein
prb
promot
cell
cycl
entri
howev
healthi
cell
target
host
cell
cycl
regul
prb
adenovir
protein
result
abort
apoptosi
clearanc
viru
abil
easili
attenu
viral
pathogen
encod
larg
foreign
transgen
make
adenoviru
attract
vector
clinic
develop
serotyp
adenoviru
classifi
categori
ag
base
viral
properti
agglutin
oncogen
potenti
rodent
model
group
c
adenovirus
nononcogen
particular
serotyp
evalu
potenti
oncolyt
agent
earli
result
clinic
trial
carri
late
cervic
cancer
demonstr
limit
therapeut
activ
live
replic
adenoviru
may
explain
part
limit
express
car
cancer
cell
recent
report
adenoassoci
viru
aav
contamin
adenoviru
prepar
result
enhanc
oncolyt
activ
adenoviru
may
one
strategi
improv
therapeut
activ
date
clinic
trial
shown
oncolyt
adenoviru
therapi
result
advers
event
demonstr
favour
safeti
profil
adenovir
genom
rel
easi
modifi
transgen
kb
insert
without
disrupt
viral
infect
therefor
adenovirus
engin
target
surfac
receptor
univers
upregul
cancer
cell
concept
clinic
evalu
ovarian
cancer
use
modifi
viru
ovarian
cancer
variabl
express
pattern
car
viru
capsid
modifi
incorpor
rgd
argglyasp
motif
hi
loop
fibr
knob
portion
outer
layer
adenoviru
capsid
modif
permit
cell
entri
bind
adenoviru
receptor
includ
integrin
highli
express
ovarian
cancer
cell
adenoviru
rgd
motif
enter
phase
clinic
trial
glioma
improv
target
adenovirus
mosaic
combin
serotyp
develop
specif
adenoviru
serotyp
preferenti
use
rather
car
cell
entri
express
prevent
normal
cell
recogn
complement
subsequ
elimin
cancer
cell
shown
overexpress
subvert
recognit
manner
therefor
mosaic
oncolyt
adenoviru
engin
carbind
sequenc
replac
sequenc
number
oncolyt
adenovirus
clinic
develop
design
take
advantag
aberr
signal
pathway
cancer
cell
exampl
adenoviru
psadriven
test
prostat
cancer
adenovirus
engin
use
tert
promot
promot
regul
express
adenovirus
delet
portion
inactiv
ref
viru
evalu
sever
clinic
cancer
trial
limit
respons
report
clinic
develop
halt
ref
may
renew
interest
agent
given
improv
understand
oncolyt
virus
potenti
combin
therapi
regimen
anticanc
agent
adenoviru
approv
treatment
nasopharyng
cancer
china
evalu
random
phase
iii
clinic
trial
particip
advanc
squamou
cell
carcinoma
head
neck
oesophagu
patient
random
chemotherapi
cisplatin
chemotherapyna
patient
adriamycin
patient
receiv
prior
platinum
chemotherapi
without
addit
viral
particl
per
day
intratumour
inject
consecut
day
everi
week
total
particip
complet
treatment
evalu
respons
patient
treat
respons
rate
compar
cohort
patient
receiv
viru
group
respons
rate
number
particip
group
small
n
signific
differ
respons
rate
patient
receiv
compar
patient
treat
chemotherapi
alon
main
advers
event
report
includ
fever
inject
site
reaction
flulik
symptom
base
result
chines
regulatori
agenc
approv
treatment
nasopharyng
carcinoma
combin
chemotherapi
vaccinia
viru
member
poxviru
famili
larg
dsdna
genom
kb
vaccinia
viru
replic
entir
cytoplasm
infect
cell
concern
regard
potenti
insert
mutagenesi
elimin
vaccinia
also
infect
wide
rang
cell
highli
tropic
tumour
cell
thought
enter
host
cell
endocyt
process
cell
membran
featur
make
vaccinia
viru
attract
vector
oncolyt
viru
develop
furthermor
vaccinia
infect
rel
innocu
immunocompet
peopl
although
result
system
ill
immunocompromis
patient
vaccinia
infect
induc
potent
cellular
humor
immun
respons
potenti
vaccinia
viru
gener
potent
immun
well
demonstr
via
use
attenu
version
vaccinia
viru
vaccin
smallpox
led
success
erad
diseas
vaccinia
viru
attenu
use
vaccin
oncolyt
agent
specif
viral
tk
vaccinia
growth
factor
vgf
vaccinia
type
ifnbind
protein
modifi
increas
cancer
cell
select
lysi
base
import
immun
respons
abil
vaccinia
viral
genom
accept
larg
transgen
kb
vaccinia
viru
engin
express
tumour
antigen
cell
costimulatori
molecul
inflammatori
cytokin
specif
express
tumour
antigen
psa
cea
mucin
vaccinia
viru
result
present
tumour
antigen
context
potent
antivir
respons
gener
enhanc
antigenspecif
antitumour
immun
respons
furthermor
vaccinia
viru
express
costimulatori
molecul
combin
lymphocyt
functionassoci
antigen
combin
term
tricom
provid
costimulatori
signal
need
antitumour
cell
shown
clinic
activ
accept
safeti
profil
earlyphas
clinic
trial
vaccinia
vector
encod
tumour
antigen
costimulatori
molecul
use
clinic
develop
system
vaccin
studi
focus
use
vector
oncolyt
agent
oncolyt
virus
demonstr
toler
safeti
profil
abil
modul
tumour
microenviron
provid
ration
strategi
combin
treatment
cancer
agent
improv
therapeut
respons
oncolyt
virus
easili
combin
wide
rang
therapi
includ
surgic
resect
chemotherapi
radiat
therapi
hormon
therapi
target
therapi
immunotherapi
inde
adenoviru
reoviru
herp
simplex
viru
type
parvoviru
clinic
evalu
combin
surgic
resect
chemotherapi
radiat
therapi
rational
combin
base
expect
oncolyt
virus
would
unaffect
therapi
abl
target
residu
cancer
follow
standardofcar
treatment
concept
also
appli
adenovirus
combin
hormon
therapi
prostat
cancer
perhap
promis
strategi
combin
oncolyt
virus
cell
checkpoint
inhibitor
recent
advanc
develop
checkpoint
inhibitor
suggest
potent
agent
activ
wide
rang
cancer
studi
suggest
patient
tumour
express
high
level
program
cell
death
ligand
may
improv
respons
cell
checkpoint
inhibitor
oncolyt
virus
often
induc
interferon
ifn
releas
local
tumour
microenviron
ifn
known
upregul
express
tumour
cell
combin
especi
interest
fact
preclin
model
valid
approach
sever
clinic
trial
way
preliminari
report
phase
ib
trial
tvec
ipilimumab
support
ad
therapeut
benefit
combin
therapi
vaccinia
viru
encod
cell
costimulatori
molecul
test
phase
clinic
trial
patient
advanc
melanoma
viru
found
safe
patient
develop
melanomaspecif
cell
respons
patient
evid
tumour
regress
includ
one
complet
respons
vaccinia
viru
encod
tricom
rvtricom
also
evalu
phase
melanoma
trial
respons
rate
studi
advers
event
gener
mild
consist
flulik
symptom
local
inject
site
reaction
sever
patient
develop
autoimmun
vitiligo
howev
clinic
develop
hold
vaccinia
viru
encod
gmcsf
also
enter
clinic
trial
random
dosefind
studi
patient
advanc
hepatocellular
carcinoma
receiv
lowdos
pfu
n
highdos
pfu
n
intratumour
inject
fewer
lesion
day
viral
replic
gmcsf
express
note
therapeut
respons
overal
object
respons
rate
includ
respons
distant
uninject
lesion
report
modifi
recist
criteria
respons
evalu
criteria
solid
tumour
similar
dose
median
surviv
howev
higher
patient
receiv
highdos
viru
month
compar
patient
treat
lowdos
month
hazard
ratio
p
data
use
justifi
phase
iii
clinic
trial
coxsackieviru
nonenvelop
singlestrand
rna
enteroviru
member
picornavirida
famili
coxsackieviru
replic
cytosol
without
dna
phase
elimin
possibl
insert
mutagenesi
infect
two
coxsackieviru
subgroup
b
differenti
base
pathogenesi
murin
model
coxsackieviru
distinguish
serotyp
group
six
distinct
serotyp
group
b
coxsackieviru
infect
gener
asymptomat
sometim
manifest
common
coldlik
symptom
coxsackieviru
util
daf
cell
entri
coxsackieviru
cavatak
viralyt
ltd
natur
tropism
cancer
cell
cancer
cell
multipl
myeloma
melanoma
breast
cancer
cell
overexpress
andor
daf
addit
direct
lysi
tumour
cell
coxsackieviru
shown
enhanc
immun
respons
part
promot
releas
damp
exampl
calreticulin
atp
coxsackieviru
infect
promot
infiltr
immun
effector
cell
includ
nk
cell
cell
enhanc
antigen
present
activ
dendrit
cell
furthermor
increas
releas
type
ifn
may
enhanc
antitumour
immun
respons
key
advantag
coxsackieviru
oncolyt
agent
includ
fact
viru
requir
complex
genet
manipul
safeti
oncolyt
activ
strong
immun
respons
induc
infect
potenti
obstacl
use
coxsackieviru
oncolyt
viru
peopl
may
previous
expos
nativ
coxsackieviru
may
immun
infect
howev
antibodi
differ
serotyp
appear
crossreact
therefor
altern
treatment
differ
serotyp
may
prevent
prematur
viral
clearanc
clinic
trial
initi
promis
earli
result
suggest
therapeut
activ
melanoma
accept
safeti
profil
see
supplementari
inform
tabl
combin
studi
cavatak
cell
checkpoint
inhibitor
melanoma
anticip
ndv
singlestrand
rna
envelop
avian
paramyxoviru
rang
size
nm
ndv
infect
cell
plasma
membran
fusion
direct
endocytosi
viru
ndv
replic
cytoplasm
infect
cell
subject
insert
mutagenesi
infect
asymptomat
human
viru
highli
sensit
type
ifn
ndv
viral
protein
trigger
potent
type
ifn
respons
case
oncolyt
virus
sensit
ndv
type
ifn
confer
cancer
cell
specif
sensit
ndvmediat
apoptosi
also
confer
cancer
cell
overexpress
bclx
l
ref
ndv
induc
cancer
cell
apoptosi
directli
activ
innat
immun
system
increas
cytokin
product
type
ifn
rant
regul
activ
normal
cell
express
secret
also
known
gmcsf
improv
antigen
present
ndv
protein
haemagglutininneuraminidas
act
potent
antigen
augment
cytolyt
cell
respons
infect
tumour
cell
thu
ndvinduc
apoptosi
cancer
cell
result
convers
immunesuppress
tumour
microenviron
proinflammatori
environ
support
antitumour
immun
respons
interestingli
even
low
titr
ndv
limit
tumour
growth
suggest
key
factor
therapeut
activ
may
gener
antitumour
immun
respons
addit
despit
rel
small
genom
kb
ndv
allow
insert
foreign
gene
insert
noncod
region
without
requir
delet
ndv
viral
gene
demonstr
gmcsf
express
local
deliveri
rather
system
administr
shown
enhanc
antitumour
respons
although
numer
preclin
studi
suggest
ndv
antitumour
activ
wide
varieti
cancer
limit
number
clinic
trial
progress
present
tabl
see
supplementari
inform
tabl
contrast
mani
oncolyt
virus
seroposit
ndv
minim
human
howev
immun
respons
gener
ndv
potent
limit
maximum
toler
dose
human
thu
dose
regimen
util
initi
low
dose
follow
higher
dose
recommend
clinic
trial
reovirus
doublestrand
nonenvelop
rna
virus
outer
surfac
icosahedr
capsid
inner
core
viral
prolifer
occur
cytoplasm
infect
cell
healthi
cell
reoviru
begin
transcript
produc
viral
rna
aid
replic
also
activ
pkr
pathway
howev
rastransform
cancer
cell
pkr
pathway
block
thu
reoviru
preferenti
target
rasmut
cancer
natur
tropism
led
mani
clinic
trial
multitud
cancer
type
includ
glioma
melanoma
ovarian
cancer
colorect
cancer
tabl
see
supplementari
inform
tabl
human
popul
commonli
expos
reoviru
healthi
cell
resist
reovir
replic
patholog
typic
subclin
howev
complic
use
reoviru
potenti
oncolyt
viral
therapi
particip
across
sever
trial
shown
seroposit
neutral
antibodi
reoviru
measl
viru
negativestrand
rna
paramyxoviru
measur
nm
diamet
genom
kb
contain
six
gene
encod
eight
protein
measl
viru
use
signal
lymphocyt
activ
molecul
slam
receptor
primarili
express
lymphocyt
andor
enter
cell
upon
cell
entri
measl
viru
remain
within
cytoplasm
undergo
replic
produc
viral
rna
capsid
protein
measl
viru
propag
infect
via
celltocel
fusion
result
format
multicellular
aggreg
ultim
cell
death
howev
measl
viru
caus
seriou
ill
human
thu
requir
widespread
vaccin
prevent
diseas
patholog
wildtyp
viru
limit
use
oncolyt
therapeut
agent
howev
attenu
strain
safer
specif
edmonston
strain
preferenti
lyse
cancer
cell
enter
ref
case
studi
document
spontan
tumour
regress
associ
coincid
measl
infect
especi
haematolog
malign
recent
edmonston
strain
measl
viru
evalu
sever
clinic
trial
multipl
tumour
type
includ
gbm
multipl
myeloma
ovarian
cancer
tabl
see
supplementari
inform
tabl
similar
oncolyt
virus
therapi
measl
viru
complic
preexist
neutral
antibodi
mani
patient
may
expos
vaccin
measl
viru
vaccin
associ
neutral
antibodi
longterm
memori
respons
result
rapid
clearanc
viru
clinic
research
need
better
defin
therapeut
activ
oncolyt
measl
virus
polioviru
nonenvelop
singlestrand
rna
picornaviru
measur
nm
diamet
polioviru
enter
cell
bind
follow
intern
viru
undergo
replic
within
cytoplasm
polioviru
highli
pathogen
human
result
paralyt
poliomyel
infect
individu
owe
destruct
anterior
horn
motor
neuron
follow
infect
thu
polioviru
need
attenu
use
oncolyt
vector
attenu
strain
sabin
shown
particular
tropism
glioma
cell
like
relat
upregul
tumour
cell
reduc
neurovirul
polioviru
attenu
replac
viral
intern
ribosom
entri
site
ire
ire
relat
human
rhino
viru
type
construct
term
pvsripo
addit
replac
polioviru
ire
ire
enhanc
select
pvsripo
gbm
ire
bind
heterodim
compris
cellular
doublestrand
rnabind
protein
also
known
nuclear
factor
activ
cell
kda
also
known
interact
block
viral
replic
healthi
neuron
cell
occur
glioma
cell
preclin
success
pvsripo
gbm
tumour
model
led
ongo
phase
clinic
trial
gbm
larg
number
oncolyt
virus
propos
cancer
therapi
includ
vsvrhabdoviru
seneca
valley
viru
parvoviru
retrovirus
agent
earli
stage
clinic
develop
clinic
studi
need
valid
approach
uniqu
challeng
develop
oncolyt
virus
new
class
anticanc
drug
includ
need
practic
clinic
trial
design
end
point
respons
assess
criteria
valid
pharmacodynam
pharmacokinet
pkpd
assay
biosafeti
issu
nontradit
regulatori
manufactur
commerci
issu
oncolyt
virus
differ
standard
drug
sever
uniqu
way
live
virus
prolifer
upon
clinic
administr
result
variabl
effect
dose
present
littl
data
avail
correl
viral
dose
vivo
replic
potenti
therapeut
respons
investig
relat
viral
replic
clinic
respons
relev
preclin
model
clinic
trial
import
establish
safe
effect
dose
guidelin
oncolyt
virus
remov
result
cell
metabol
bind
circul
protein
rather
subject
host
antivir
immun
respons
multipl
factor
need
consid
regard
includ
preexist
neutral
antibodi
titr
virusspecif
memori
cell
respons
potenti
disabl
virus
haemagglutinin
bind
innat
abil
viru
evad
immun
detect
addit
mani
tumour
microenviron
highli
immunesuppress
limit
host
immun
respons
studi
evalu
preexist
antivir
immun
induct
posttreat
immun
respons
viral
vector
tumourassoci
antigen
import
better
understand
dynam
oncolyt
virus
clear
control
patient
cancer
biosafeti
consider
oncolyt
virus
thu
far
associ
rel
toler
safeti
profil
numer
clinic
trial
conduct
across
wide
rang
cancer
nonetheless
replic
potenti
agent
requir
attent
infect
control
issu
includ
procedur
safe
storag
prepar
handl
administr
viru
true
potenti
infect
depend
natur
viru
comorbid
condit
within
patient
close
household
contact
healthcar
worker
may
expos
viru
addit
mani
oncolyt
virus
contain
recombin
dna
element
potenti
impact
gene
segment
potenti
recombin
wildtyp
virus
environ
theoret
concern
although
univers
accept
standard
respect
biosafeti
oncolyt
virus
development
plan
includ
polici
safe
handl
storag
agent
guidelin
healthcar
worker
especi
pharmacist
prepar
agent
physician
nurs
administ
agent
establish
agent
safe
manag
standard
univers
precaut
addit
educ
materi
need
develop
viru
clear
instruct
deal
accident
spill
clean
treatment
room
patient
visit
instruct
possibl
antidot
event
accident
exposur
case
warn
issu
patient
healthcar
worker
avoid
contact
agent
exampl
immunocompromis
individu
pregnant
women
expos
vaccinia
viru
plan
manag
viru
administr
site
also
clearli
delin
patient
healthcar
worker
event
possibl
contamin
bandag
dress
plan
proper
dispos
healthcar
set
home
develop
oncolyt
virus
new
agent
potenti
dissemin
mani
plan
may
need
consid
expand
surveil
programm
present
clear
regulatori
agenc
manag
biosafeti
issu
consider
postmarket
risk
evalu
mitig
strategi
rem
process
may
indic
despit
theoret
concern
note
report
household
transmiss
oncolyt
virus
literatur
date
also
import
note
mani
oncolyt
virus
attenu
nativ
strain
often
ubiquit
environ
howev
isol
case
exposur
healthcar
profession
handl
oncolyt
virus
laboratori
patient
administr
case
gener
without
signific
sequela
although
individu
requir
treatment
antivir
agent
clinic
trial
design
respons
assess
recent
evid
suggest
kinet
immunemedi
respons
may
much
slower
compar
therapeut
agent
directli
kill
tumour
cell
activ
immun
system
result
indirect
method
tumour
cell
kill
requir
prime
expans
immun
effector
cell
notabl
cytotox
cell
time
cell
undergo
homeostat
expans
traffick
site
tumour
growth
lytic
destruct
cancer
cell
inflammatori
clearanc
necrot
tumour
fig
may
result
term
pseudoprogress
clinic
trial
must
consid
nontradit
end
point
account
emerg
delay
therapeut
respons
pseudoprogress
may
complic
interpret
clinic
result
consid
futur
oncolyt
viru
trial
addit
oncolyt
virus
repres
challeng
respect
subject
elig
dose
biodistribut
assess
design
clinic
trial
mani
clinic
studi
util
local
deliveri
viru
patient
tumour
must
access
inject
date
viru
dose
typic
base
maximum
concentr
viru
possibl
current
purif
techniqu
volum
tumour
determin
viru
administr
quit
cumbersom
studi
adequ
explor
associ
viru
dose
therapeut
respons
occurr
advers
event
nonetheless
oncolyt
virus
replic
within
tumour
tissu
even
small
dose
may
result
signific
clinic
activ
provid
viru
rapidli
clear
immun
system
observ
clinic
trial
oncolyt
polioviru
tvec
final
individu
assay
assess
viru
distribut
need
evalu
pharmacodynam
viru
deliveri
ideal
includ
data
presenc
viru
within
target
cell
exampl
cancer
cell
lack
viral
replic
nontarget
cell
viru
shed
within
bodi
fluid
evid
latent
infect
viral
clearanc
virusspecif
tumourspecif
humor
cellular
immun
respons
although
mani
trial
made
progress
establish
assay
standard
agreement
within
field
valid
correl
end
point
sever
strategi
clinic
assess
oncolyt
virus
vivo
develop
common
method
determin
tissu
uptak
use
express
fluoresc
dye
green
fluoresc
protein
gfp
luciferas
viral
vector
quantit
viral
transcript
within
infect
cell
techniqu
howev
challeng
patient
requir
inclus
foreign
transgen
unknown
clinic
consequ
potenti
immun
recognit
difficulti
imag
fluoresc
activ
deep
tissu
layer
contrast
measl
viru
engin
express
protein
enzym
reli
fluoresc
vivo
monitor
measl
viru
engin
encod
solubl
extracellular
domain
human
cea
upstream
nucleoprotein
gene
allow
quantit
monitor
viral
gene
express
serial
peripher
blood
measur
cea
level
anoth
interest
strategi
util
measl
viru
express
human
thyroid
sodium
iodid
symport
ni
ni
concentr
radioact
iodin
monitor
use
singl
photon
emiss
comput
tomographi
spect
positron
emiss
tomographi
pet
imag
encod
viral
tk
mutat
dopamin
receptor
use
trap
radioact
tracer
monitor
viru
locat
replic
abil
system
viral
tk
phosphoryl
inject
radioact
ilabel
fiau
trap
radioact
signal
within
cell
mutat
dopamin
receptor
act
similar
fashion
trap
radioact
tracer
monitor
use
pet
imag
addit
imag
tumour
biopsi
procedur
perform
access
appropri
determin
viral
titr
target
nontarget
tissu
tumour
biopsi
sampl
provid
function
data
well
inform
kinet
propag
oncolyt
viru
collect
bodi
tissu
includ
blood
saliva
urin
may
also
provid
indic
viral
replic
critic
ensur
safeti
determin
bioshed
dynam
therapeut
oncolyt
virus
regulatori
commerci
issu
live
replic
natur
oncolyt
virus
pose
uniqu
regulatori
manufactur
issu
virus
propag
tissu
cultur
requir
method
hightitr
viru
product
test
adventiti
pathogen
assess
viru
puriti
replic
potenti
thu
procedur
laboratori
safeti
manufactur
vial
product
valid
puriti
qualiti
design
result
gener
biolog
cell
cultur
must
consid
virus
difficult
gener
high
titr
lysat
requir
clinic
dose
challeng
biotechnolog
manufactur
aspect
review
extens
elsewher
viral
vaccin
provid
templat
manufactur
regul
oncolyt
virus
fda
publish
draft
guidanc
document
titl
guidanc
industri
design
analysi
shed
studi
viru
bacteriabas
gene
therapi
oncolyt
product
relev
document
includ
european
director
qualiti
medicin
includ
cell
substrat
product
vaccin
human
use
ref
test
extran
agent
viral
vaccin
human
use
ref
provid
guidelin
qualiti
control
test
materi
cell
use
gener
oncolyt
virus
furthermor
intermedi
viral
batch
need
test
contamin
efficaci
howev
remov
contamin
especi
microbi
viral
contamin
prove
difficult
oncolyt
virus
recombin
protein
method
use
remov
contamin
may
also
target
oncolyt
viru
qualiti
oncolyt
viru
prepar
test
control
cell
standard
readout
combin
virusspecif
neutral
antibodi
confirm
effect
mediat
viru
approach
adapt
method
use
test
human
viral
vaccin
infrastructur
provid
addit
framework
need
widespread
commerci
oncolyt
virus
cancer
therapi
demonstr
signific
improv
durabl
respons
patient
melanoma
treat
tvec
revolution
field
anticanc
therapi
oncolyt
virus
howev
develop
oncolyt
virus
therapeut
agent
requir
care
attent
establish
appropri
clinic
trial
design
dose
regimen
pharmacodynam
assay
educ
programm
address
biosafeti
concern
well
new
manufactur
regulatori
pathway
likewis
care
attent
patient
select
also
import
consider
exampl
immunocompromis
patient
may
good
candid
oncolyt
virusmedi
antitumour
immun
could
compromis
patient
nevertheless
oncolyt
virus
associ
favour
riskbenefit
ratio
continu
develop
new
class
drug
anticip
particular
interest
combin
approach
oncolyt
viru
immunotherapi
highli
promis
approach
introduc
new
class
drug
treat
patient
cancer
